Publikationen in Zusammenarbeit mit Forschern von Centro de Investigación Biomédica en Red sobre Enfermedades Hepáticas y Digestivas (52)

2024

  1. Neddylation orchestrates the complex transcriptional and posttranscriptional program that drives Schwann cell myelination

    Science Advances, Vol. 10, Núm. 15

  2. p63 controls metabolic activation of hepatic stellate cells and fibrosis via an HER2-ACC1 pathway

    Cell Reports Medicine, Vol. 5, Núm. 2

2023

  1. Hepatic levels of S-adenosylmethionine regulate the adaptive response to fasting

    Cell Metabolism, Vol. 35, Núm. 8, pp. 1373-1389.e8

  2. Hepatocyte-specific O-GlcNAc transferase downregulation ameliorates nonalcoholic steatohepatitis by improving mitochondrial function

    Molecular Metabolism, Vol. 75

  3. The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent

    Hepatology (Baltimore, Md.), Vol. 78, Núm. 3, pp. 878-895

2022

  1. Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function

    Journal of Hepatology, Vol. 76, Núm. 1, pp. 11-24

  2. Inhibition of carnitine palmitoyltransferase 1A in hepatic stellate cells protects against fibrosis

    Journal of Hepatology, Vol. 77, Núm. 1, pp. 15-28

  3. Methionine adenosyltransferase 1a antisense oligonucleotides activate the liver-brown adipose tissue axis preventing obesity and associated hepatosteatosis

    Nature Communications, Vol. 13, Núm. 1

  4. Mitochondrial bioenergetics boost macrophage activation, promoting liver regeneration in metabolically compromised animals

    Hepatology, Vol. 75, Núm. 3, pp. 550-566

2021

  1. Boosting mitochondria activity by silencing MCJ overcomes cholestasis-induced liver injury

    JHEP Reports, Vol. 3, Núm. 3

  2. Magnesium accumulation upon cyclin M4 silencing activates microsomal triglyceride transfer protein improving NASH

    Journal of Hepatology, Vol. 75, Núm. 1, pp. 34-45

  3. O-GlcNAcylated p53 in the liver modulates hepatic glucose production

    Nature Communications, Vol. 12, Núm. 1

2020

  1. HuR/ELAVL1 drives malignant peripheral nerve sheath tumor growth and metastasis

    The Journal of clinical investigation, Vol. 130, Núm. 7, pp. 3848-3864

  2. Silencing hepatic MCJ attenuates non-alcoholic fatty liver disease (NAFLD) by increasing mitochondrial fatty acid oxidation

    Nature Communications, Vol. 11, Núm. 1

  3. Targeting Hepatic Glutaminase 1 Ameliorates Non-alcoholic Steatohepatitis by Restoring Very-Low-Density Lipoprotein Triglyceride Assembly

    Cell Metabolism, Vol. 31, Núm. 3, pp. 605-622.e10

2019

  1. Fine-Tuning of Sirtuin 1 Expression Is Essential to Protect the Liver From Cholestatic Liver Disease

    Hepatology, Vol. 69, Núm. 2, pp. 699-716

  2. SUMOylation regulates LKB1 localization and its oncogenic activity in liver cancer

    EBioMedicine, Vol. 40, pp. 406-421

  3. Ubiquitin-Like Post-Translational Modifications (Ubl-PTMs): Small Peptides with Huge Impact in Liver Fibrosis

    Cells, Vol. 8, Núm. 12

  4. miR-873-5p targets mitochondrial GNMT-Complex II interface contributing to non-alcoholic fatty liver disease

    Molecular Metabolism, Vol. 29, pp. 40-54

2018

  1. MiR-873-5p acts as an epigenetic regulator in early stages of liver fibrosis and cirrhosis

    Cell Death and Disease, Vol. 9, Núm. 10